epcoritamab,rituximab
janssen,abbvie,roche,biogen,genmab
['nhl', 'follicular', 'epcore,nhl,2', 'epcore nhl-2', 'lymphoma', 'abbvie']
 updates:
at the ongoing asco 2022 conference, / presented spectacular findings from arm 2 of the epcore nhl-2 (phase ib/ii) trial in patients with r/r follicular lymphoma. check out more, at: #asco2022 #oncology #oncologist #cancer 
#DelveInsight is a premier Business Consulting and Market Research firm, focused exclusively on the healthcare industry